Welcome to our dedicated page for Ardelyx SEC filings (Ticker: ARDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ardelyx, Inc. filings document a commercial-stage biopharmaceutical company with U.S. product revenue from IBSRELA and XPHOZAH and development activity centered on tenapanor and NHE3 inhibition. Form 8-K reports cover quarterly operating results, preliminary product sales, cash and investment updates, Regulation FD presentation materials, and other material-event disclosures tied to the company’s commercial and clinical programs.
Ardelyx proxy materials describe annual meeting proposals, director elections, say-on-pay matters, auditor ratification, executive compensation, board structure, and stockholder voting mechanics. Additional current reports record officer appointments, executive transitions, transition and separation agreements, compensatory arrangements, governance matters, and disclosure controls relevant to the company’s public-company reporting obligations.
ARDX filed an amended Form 144/A disclosing a proposed sale of common stock, listing 10,388 shares tied to restricted stock unit vesting on 02/19/2026. The filing also reports a prior sale by Joseph James Reilly of 11,086 shares on 11/21/2025.
Laura A. Williams reports proposed sale of 24,041 shares of Common Stock. The filing lists 24,041 shares associated with the vesting of restricted stock units on 02/19/2026, described as arising from services rendered.
The notice also records sales during the prior three months: 6,426 shares on 11/21/2025 for $35,580.12 and 50,000 shares on 01/08/2026 for $348,900.00. The broker listed is Morgan Stanley Smith Barney LLC.
ARDX submitted a Form 144 reporting proposed sales of Common Stock. The filing lists 11,800 shares, notes 24,986 shares tied to the vesting of restricted stock units on 02/19/2026, and discloses a prior sale of 5,560 shares on 11/21/2025.
ARDX affiliate filed a notice to sell common stock. The filing identifies the vesting of 10,388 restricted stock units on 02/19/2026 as the source of securities to be sold. The filing also records a prior sale of 11,086 shares on 11/21/2025 for $61,382.07.
Eric Duane Foster submitted a notice of proposed sale of 28,415 shares of Common Stock following vesting of restricted stock units on 02/19/2026. The filing also discloses a prior sale of 5,814 shares on 11/21/2025 and lists Morgan Stanley Smith Barney LLC as the broker.
ARDX insider filing notifies a proposed resale of 51,100 shares of common stock through Morgan Stanley Smith Barney LLC, dated 02/20/2026. The filing also lists 108,840 shares issued on 02/19/2026 upon vesting of restricted stock units for services rendered. The filing records a prior sale by Michael Raab of 46,887 shares on 11/21/2025 for $259,608.63.
ARDX submitted a Form 144 notice relating to Common Stock tied to the vesting of restricted stock units. The excerpt shows 5,355 shares associated with vesting on 02/19/2026, with broker Morgan Stanley Smith Barney LLC listed.
Ardelyx filed a Form 144 notice to sell 7,771 shares of common stock following the vesting of restricted stock units on 02/19/2026. The filing lists Morgan Stanley Smith Barney LLC as the broker and indicates the shares relate to services rendered.
ARDX submitted a Form 144 notice regarding Common Stock. The filing lists a 3,000 share entry associated with a broker and a separate 6,216 share item tied to the vesting of restricted stock units dated 02/19/2026.
The broker named is Morgan Stanley Smith Barney LLC; the vesting is shown as for services rendered.
Ardelyx, Inc. filed its Form 10-K describing a commercial-stage biopharma business built around tenapanor, marketed as IBSRELA for IBS‑C and XPHOZAH for dialysis patients with hyperphosphatemia. The company is expanding tenapanor into chronic idiopathic constipation through the Phase 3 ACCEL trial and advancing a next‑generation NHE3 inhibitor, RDX10531.
The filing highlights that XPHOZAH’s inclusion in the ESRD Prospective Payment System on January 1, 2025 eliminated Medicare Part D coverage, causing a negative and material impact on 2025 XPHOZAH revenue and pointing to slower future growth. Ardelyx reports cash, cash equivalents and short‑term investments of $264.7 million and $200 million of term debt outstanding as of December 31, 2025, plus an unused at‑the‑market equity program of up to $100 million. Management emphasizes ongoing losses since inception, reliance on growing IBSRELA and XPHOZAH sales, and potential need for additional financing while it continues to invest in commercialization and pipeline development.